Navigation Links
TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
Date:5/14/2009

MONMOUTH, N.J., May 14 /PRNewswire/ -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today at the 30th Annual Scientific Sessions of the Heart Rhythm Society the initial, interim clinical results from its AIGISRX(TM) Antibacterial Envelope Retrospective Registry.

AIGIS is an anti-bacterial mesh envelope developed to deliver anti-microbial agents that help provide protection against infections associated with implanted pacemakers and cardioverter defibrillators. AIGIS also securely holds a pacemaker (PM) or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body.

During the Heart Rhythm Society 2009 Annual Scientific Sessions*, TYRX held an AIGIS Retrospective Registry (ARR) Investigator's Meeting at which the study's early results were presented and discussed. The intent of the IRB-sanctioned, multi-centered, retrospective study is to define the implant success rate and incidence of infection, in patients implanted with cardiac rhythm management device (CRMD) and the AIGIS.

To date, 393 patients from seven (7) clinical sites have been enrolled in the study with a 98% success rate of CRMD implantation, with the 2% of failures not being AIGIS related. Of the 393 patients enrolled, at least one follow-up visit has been completed for 254 patients with a mean follow-up period of 59 days and a median follow-up of 32 days. Noting that De Oliveira et al.(1) report the median time to CRMD infection as 14 days, and Klug et al.(2) reported a median time to infection of 52 days, the preliminary infections rates in the ARR are as follows:

    All Patients w/ greater than or equal to 1 Follow-up

                               PM                           ICD/CRT
                                       infection                     infection
     Implant Type  implants infections   rate    implants infections    rate
    De novo           15        0        0.0%       51        0         0.0%
    Revision          38        0        0.0%      141        5         2.0%
    Total             53        0        0.0%      192        5         2.0%

                              Other                         Total
                                       infection                     infection
     Implant Type  implants infections   rate    implants infections    rate
    De novo            1        0        0.0%       67        0         0.0%
    Revision           8        0        0.0%      187        5         2.0%
    Total              9        0        0.0%      254        5         2.0%




    All Patients w/ greater than or equal to 1 Follow-up & CRMD
     Infection designation restricted to Generator Pocket Infections Only

                               PM                           ICD/CRT
                                       infection                     infection
     Implant Type  implants infections   rate    implants infections   rate
    De novo           15        0        0.0%       51        0        0.0%
    Revision          38        0        0.0%      141        3        1.2%
    Total             53        0        0.0%      192        3        1.2%

                              Other                          Total
                                       infection                     infection
     Implant Type  implants infections   rate    implants infections   rate
    De novo            1        0        0.0%       67        0        0.0%
    Revision           8        0        0.0%      187        3        1.2%
    Total              9        0        0.0%      254        3        1.2%



    All Patients w/ greater than or equal to 1 Follow-up & CRMD Infection
     designation restricted to Generator Pocket Infections w/o CRMD infection
     in prior 6 mos.
                               PM                           ICD/CRT
                                       infection                     infection
     Implant Type  implants infections   rate    implants infections   rate
    De novo           15        0        0.0%       51        0        0.0%
    Revision          38        0        0.0%      141        1        0.4%
    Total             53        0        0.0%      192        1        0.4%

                              Other                           Total
                                      infection                      infection
     Implant Type implants infections   rate     implants infections   rate
    De novo           1        0        0.0%        67         0       0.0%
    Revision          8        0        0.0%       187         1       0.4%
    Total             9        0        0.0%       254         1       0.4%

Dr. Dan Lerner, TYRX's Chief Medical Officer, noted that "when one looks at the characteristics of the patients enrolled in the AIGIS Retrospective Registry to-date it is noteworthy that there is a high percentage of patients who are, according to published studies, at high risk of CRMD-related infections."

                                                             Greater than
                                                             or equal to 1
                                                              Follow-up
       Risk Factors for developing a CRMD       All            Visit
                    infection                 n = 393          n = 254
                                              n     %         n      %
                                     CHF     218   55.5      152    59.8

             Chronic Renal Insufficiency      93   23.7       56    22.1

                   Chronic Renal Failure      41   10.4       24     9.5

                     Oral anti-coagulant     140   35.6       90    35.4

                      Corticosteroid use      30    7.6       22     8.7

                   Temporary pacing wire       8      2        3    1.18

                      > 2 leads in place     163   41.5      105    41.3

                          Device Revsion     278   70.7      187    73.6

                    Early reintervention       9    2.3        9     3.5

Dr. Dan Lerner continued, "Of the 3 generator pocket infections reported to date, 2 occurred in patients who had prior explants for infection within the past 6 months. Importantly, these early data indicate AIGIS does not interfere with CRMD implant success. The AIGIS Retrospective Registry continues with the expectation that, with the enrollment of 3 additional clinical sites, TYRX will collect data on over 500 AIGIS patients, representing more than 15% of the 3,000 AIGIS implanted to-date. The company plans to continue the AIGIS Retrospective Registry follow-up period will provide clinicians greater insight into the clinical utility of AIGIS."

"We are delighted these data indicate clinicians are using AIGIS in the full spectrum of CRMD implant procedures. In particular, it is gratifying to see that AIGIS is being used in patients who are at very high risk for CRMD infection," added Bill Edelman, CEO of TYRX, Inc. "In addition to the AIGIS Retrospective Registry, we have begun the process of recruiting approximately 20 clinical sites for the AIGIS Prospective Registry, which will follow AIGIS patients for 12 months and compare the incidence of infection to published historical and case-matched controls of cardiac rhythm management device (CRMD) recipients. TYRX is committed to better understanding how the AIGIS envelope can help the greatest number of patients."

Additional information regarding TYRX, Inc.'s Retrospective and Prospective Registries, and associated clinical results, can be found at www.TYRX.com.

About TYRX, Inc.

TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products, including the AIGISRX(TM) Anti-Bacterial Envelope. AIGIS contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm device related endocarditis, including "superbugs" or MRSA. In addition, AIGIS is intended to securely hold a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. Following commercial release in June, 2008, AIGIS has been implanted in over 3,000 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space.

For more information, please visit www.TYRX.com.

* This program was not part of the Heart Rhythm 2009 Official Scientific Sessions as planned by the HRS Scientific Sessions Committee.

  1. de Oliveira et al, Circulation 2009 2, 29.
  2. Klug et al, Circulation 2007 116, 1349.


'/>"/>
SOURCE TYRX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... /PRNewswire/--  Cell Applications, Inc. and Cyfuse Biomedical ... now available in North America ... approach called the "Kenzan Method." Utilizing Cyfuse Biomedical,s ... robotic system that fabricates 3D tissue from cells, ... model that makes scaffold-free tissue available immediately to ...
(Date:2/8/2016)... 2016 Velano Vascular, a medical technology company ... and their practitioners, announced today that the company has ... use the proceeds from this financing, an extension of ... 2015, to support the development and commercialization of the ... Philadelphia , and a ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016  Unilife Corporation ("Unilife" ... and supplier of injectable drug delivery systems, today announced that ... six months ended December 31, 2015 after market close on ... scheduled a conference call to discuss these financial results.    ... Unilife Corporation --> About Unilife Corporation ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, ... that they are loved. This year, for more than 5.6 million Americans suffering with ... won't be enough to remind them of the lives they’ve led and the people they’ve ...
(Date:2/8/2016)... ... , ... If you are feeling that your clothes are a tad snug, ... the Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are ... cancer, some of the leading causes of preventable death. February is heart health ...
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... executive networking and relationship-marketing firm, announced today that nominations will be accepted ... Executive® (ISE®) West Awards. , Awards include the Information Security Executive® ...
Breaking Medicine News(10 mins):